Pharnext announces that it has received two binding offers to sign an agreement valuing 'PXT3003', its most advanced drug candidate currently in a pivotal Phase III clinical trial in Charcot-Marie-Tooth disease type 1A (CMT1A), a rare disabling peripheral neuropathy, at over 250 ME.

One offer is for a license agreement with geographic exclusivity limited to the United States and Europe, enabling Pharnext to enter into further negotiations in other territories at a later date.

The other offer is for the purchase of all PXT3003 intellectual property and related contracts for worldwide exploitation, outside China.

Depending on the various future revenue projections linked to sales of the drug, total revenues for Pharnext could reach between 250 ME and up to 800 ME over the entire life of the rights.

Furthermore, in order to cover its short-term financing needs and allow the valorisation process of its main asset to continue unhindered, Pharnext announces that it has asked GTO 13 and obtained their agreement to subscribe to an additional financing of 2.5 ME over the next few days through the issue of OCEANE-BSA bonds.


Copyright (c) 2023 CercleFinance.com. All rights reserved.